- This event has passed.
Malignant Melanoma: An update for GPs
August 14 @ 7:00 pm - 8:30 pm
As part of the implementation of the Statewide Project, Optimal Care Pathways for Cancer into General Practice, Gippsland PHN proudly supports the Victorian Tasmanian Primary Health Network Alliance (VTPHNA) and North Western Melbourne PHN to present this RACGP accredited webinar. Learn the latest on the diagnosis of malignant melanoma and an update on advances in investigations and treatment from leading clinical specialists.
By the end of this session you will be able to:
- Identify malignant melanoma
- Biopsy suspicious lesions
- Implement a process to refer appropriate patients for a sentinel node biopsy
- Recognise the more frequent and the more serious side effects of some types of immunotherapy (particularly those used in treatment of malignant melanoma)
Associate Professor Victoria Mar
A/Prof Victoria Mar is the Director of the Victorian Melanoma Service at The Alfred and Adjunct Associate Professor at the School of Public Health and Preventive Medicine, Monash University. She is a board member of the Australian and New Zealand Melanoma Trials Group and the Skin and Cancer Foundation. She has authored and co-authored a number of chapters for the Cancer Council Australia Melanoma Guidelines and is Clinical Lead for the Melanoma Clinical Outcomes Registry.
Associate Professor Shahneen Sandhu
A/Prof Shahneen Sandhu is a medical oncologist and researcher with an appointment in the skin and melanoma unit at the Peter MacCallum Cancer Centre. She completed her medical oncology training at Peter MacCallum Cancer Centre and subsequently spent 6 years at the Royal Marsden NHS Foundation Trusts/Institute of Cancer Research Drug Development Unit. Over the course of her research career, A/Prof Shahneen Sandhu has made important original contributions to cancer research, particularly in the development and application of clinical biomarkers. She continues to undertake clinical and translational research in melanoma and other skin cancers.